Q3252312 (Q3252312): Difference between revisions
Jump to navigation
Jump to search
(Created a new Item) |
(Changed label, description and/or aliases in en) |
||
| description / en | description / en | ||
Project | Project Q3252312 in Spain | ||
Revision as of 14:22, 9 October 2021
Project Q3252312 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3252312 in Spain |
Statements
6,250.0 Euro
0 references
12,500.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 December 2018
0 references
PROTOQSAR 2000 SL
0 references
46250
0 references
El proyecto COPACABANA pretende introducir nano-anticuerpos elegibles para fines terapéuticos dirigidos contra Cx43, Cx32, Cx26 y Panx1, utilizando protocolos novedosos, incluida la inmunización con ADN de llamas combinada con tecnología de nano-discos. COPACABANA probará estos nano-anticuerpos por su potencial para inhibir los hemicanales y para aliviar las características patológicas en modelos en roedores de una variedad de enfermedades inflamatorias. (Spanish)
0 references
The COPACABANA eligible project aims to introduce nano-antibodies for therapeutic purposes directed against Cx43, Cx32, Cx26 and Panx1, using novel protocols including DNA immunization with combined flames nano-discs. COPACABANA test these nano-antibodies for their potential to inhibit hemichannels and to alleviate the pathological features in rodent models of a variety of inflammatory diseases. (English)
0 references
Valencia
0 references
Identifiers
20F01020101U_IVCI00000APEA8025
0 references